Clinical Value of Peripheral Blood SCC,ProGRP,CA-125 and CYFRA21-1 in the Diagnosis and Prognostic Assessment of Non-small Cell Lung Cancer
Objective To explore the clinical value of peripheral blood squamous cell carcinoma antigen(SCC),progas-trin releasing peptide(ProGRP),carbohydrate cancer antigen 125(CA125)and cytokeratin fragment 19(CYFRA21-1)in the diag-nosis and prognostic assessment of non-small cell lung cancer(NSCLC).Methods A total of 90 patients with NSCLC treated in the hospital were enrolled as lung cancer group,82 cases benign lung lesions were selected as the benign group and 90 healthy subjects who underwent physical examination during the same period were selected as the control group.The levels of peripheral blood SCC,ProGRP,CA-125 and CYFRA21-1 in three groups were statistically analyzed.Their diagnostic efficiency were analyzed by ROC curves,and the factors influencing the prognosis of NSCLC were analyzed by logistic regression.Results The expression levels of serum SCC,ProGRP,CA-125 and CYFRA21-1 in lung cancer group were higher than those in benign group and the con-trol group(P＜0.05).The expressions of serum SCC,ProGRP,CA-125 and CYFRA21-1 in survival group were lower than those in the death group(P＜0.05).ROC curve analysis showed that the AUC of SCC combined with ProGRP,CA-125 and CYFRA21-1 for predicting the prognosis of NSCLC was 0.933,greater than that of single index(P＜0.05).Binary logistic regression analy-sis,squamous carcinoma,TNM stage T3～T4,lymph node metastasis,SCC＞1.57 ng/mL,ProGRP＞73.04 pg/mL,CA-125＞29.53 U/mL,and CYFRA21-1＞3.00 ng/mL were all risk factors for NSCLC prognosis(P＜0.05).Conclusion Peripheral blood SCC,ProGRP,CA-125,CYFRA21-1 expression is elevated in NSCLC patients and can be used for patient prognosis assess-ment.
Non-small cell lung cancerSquamous cell carcinoma antigenProgastrin releasing peptideCarbohydrate cancer antigen 125Cytokeratin fragment 19
NETL
NSTL
万方数据
